Cover Image
市場調查報告書

PharmaPoint:急性冠狀動脈症候群--日本的醫藥品預測與市場分析

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 312376
出版日期 內容資訊 英文 218 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:急性冠狀動脈症候群--日本的醫藥品預測與市場分析 PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023
出版日期: 2014年07月31日 內容資訊: 英文 218 Pages
簡介

全球主要7個國家的急性冠狀動脈症候群(ACS)治療藥的市場規模在2013年的現下達到123億美金,其中首發藥(品牌藥)為50億美元(佔整體40%),學名藥73億美元(佔整體60%)。美國在這雙方所佔的佔有率都相當高。2023年預測整體市場規模為434億美金,其中首發藥(品牌藥)為277億美元(佔整體64%),學名藥157億美元(佔整體36%)。全球各國老年人口和文明病(肥胖等)患者數持續增加、生技藥品被多方使用,將會輕易左右今後的市場動向。另一方面,ACS治療藥市場已經飽和化、成熟化,治療藥大半已經以學名藥為主。尤其是Statin已幾乎都是學名藥,可以低價提供。同時ARB(血管收縮素受體阻斷劑的)由於治療費相對較高,首發藥的佔有率正在提升。日本的ACS治療藥市場規模在2013年現下次於美國、德國、英國位居全球第4位。一般認為部分治療藥(Brilinta和Effient)的延期上市,是其市場規模相對較小的原因。

本報告提供日本的急性冠狀動脈症候群(缺血症候群,ACS)治療方法相關的最新研究·開發情形和市場未來展望分析,提供您疾病概要和治療方法,市場機會及未滿足需求,市場規模趨勢(今後10年份),已上市/臨床實驗中主要的治療藥簡介(功效·安全性·市場競爭力),及日本市場現狀與今後的方向性等資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理
    • 病因
    • 病理生理學
    • 預後
    • 生活品質(QoL)
  • 症狀

第4章 疾病的管理

  • 治療概要
  • 日本
    • 診斷
    • 臨床診療

第5章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估
  • 產品簡介
    • 纖維素溶解性(血栓溶解性)藥物:組織纖維蛋白原活性化因子(tPA)
    • Clopidogrel
    • Brilinta(ticagrelor)
    • Effient(prasugrel)
    • Integrilin(eptifibatide)
    • Warfarin
    • Angiomax(bivalirudin)
    • Arixtra(fondaparinux)及肝素
    • Statin:HMG-CoAredakutaze抑制劑
    • β腎上腺素受體拮抗劑(β受體阻斷劑)
    • Renin-Angiotensin-Aldosterone System(RAAS)抑制劑

第6章 未滿足需求與市場機會

  • 概要
  • 動脈粥狀硬化斑塊的直接治療方法
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 纖維性心肌病及相關併發症的治療方法
  • Statin耐受不良·難治性·Non-Compliant Patients的LDL-C(低密度脂蛋白膽固醇)降血脂醫藥品
  • NOAC(新型口服抗凝固劑)的解毒劑
  • 大幅降低出血風險的血液稀釋劑

第7章 開發平台評估

  • 概要
  • 臨床實驗的進展:代(PHASE)別·進展狀況別
  • 臨床實驗中的有潛力藥劑
    • Xarelto(Rivaroxaban)
    • Cangrelor
    • Zontivity(vorapaxar)
    • Alirocumab(RGN727)
    • Evolocumab(AMG 145)
    • Bococizumab(PF-04950615)
    • Anacetrapib
    • Evacetrapib
    • Darapladib

第8章 市場未來展望

  • 日本市場
    • 預測
    • 近幾年的主要趨勢
    • 市場促進·阻礙因素:全球整體的情況
    • 市場促進·阻礙因素:日本的情況

第9章 附錄

圖表一覽

目錄

GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded drug sales (40%) and $7.3bn in generic sales (60%). GlobalData expects that the ACS drug market will grow at a CAGR of 13.4% over the ten year forecast period, resulting in a market value of $43.4bn by 2023, of which 64% will be attributed to branded drug sales ($27.7bn) and 36% to generic drug sales ($15.7bn). The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

By the end of the forecast period, GlobalData projects that the Japanese market will overtake the Italian market in size, becoming the fourth largest market behind the US, Germany, and the UK. The Japanese antiplatelet market in 2013 was the smallest of all 7MM due to the pending product launches of Brilinta and Effient.

Scope

  • Overview of ACS including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan ACS market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for ACS.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in Japan.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Treatment Overview
  • 4.2. Japan
    • 4.2.1. Diagnosis
    • 4.2.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles
    • 5.3.1. Fibrinolytic (Thrombolytic) Drugs - Tissue Plasminogen Activator (tPA)
    • 5.3.2. Clopidogrel
    • 5.3.3. Brilinta (ticagrelor)
    • 5.3.4. Effient (prasugrel)
    • 5.3.5. Warfarin
    • 5.3.6. Statins - HMG-CoA Reductase Inhibitors
    • 5.3.7. Beta-Adrenergic Receptor Antagonists (Beta Blockers)
    • 5.3.8. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Therapies that Treat Fibrotic Myocardium and Associated Comorbidities
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Antidotes for New Oral Anticoagulants (NOACs)
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Blood-Thinning Agents with Significantly Reduced Bleeding Risks
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Clinical Trials by Phase and Trial Status
  • 7.3. Promising Drugs in Clinical Development
    • 7.3.1. Xarelto (rivaroxaban)
    • 7.3.2. Cangrelor
    • 7.3.3. Zontivity (vorapaxar)
    • 7.3.4. Alirocumab (RGN727)
    • 7.3.5. Evolocumab (AMG 145)
    • 7.3.6. Bococizumab (PF-04950615)
    • 7.3.7. Anacetrapib
    • 7.3.8. Evacetrapib
    • 7.3.9. Darapladib

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers - Global Issues
    • 8.1.4. Japan - Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population
    • 9.4.2. Diagnosed Acute Coronary Syndrome Patients
    • 9.4.3. Percent Drug-Treated Patients
    • 9.4.4. Drugs Included in Each Therapeutic Class
    • 9.4.5. Launch and Patent Expiry Dates
    • 9.4.6. General Pricing Assumptions
    • 9.4.7. Individual Drug Assumptions
    • 9.4.8. Generic Erosion
    • 9.4.9. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Reviewer
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Antiplatelet Agents that Inhibit Platelet Activation
  • Table 2: Anticoagulants that Inhibit the Coagulatory Cascade
  • Table 3: Symptoms of Acute Coronary Syndrome
  • Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI)
  • Table 5: Most Prescribed Drugs for ACS by Class in Japan, 2014
  • Table 6: Leading Treatments for Acute Coronary Syndrome, 2014
  • Table 7: Commonly Used tPAs
  • Table 8: Product Profile - Tissue Plasminogen Activator (tPA)
  • Table 9: Fibrinolytics SWOT Analysis, 2014
  • Table 10: Product Profile - Plavix (clopidogrel)
  • Table 11: Clopidogrel SWOT Analysis, 2014
  • Table 12: Product Profile - Brilinta (ticagrelor)
  • Table 13: Brilinta (ticagrelor) SWOT Analysis, 2014
  • Table 14: Product Profile - Effient (prasugrel)
  • Table 15: Effient (prasugrel) SWOT Analysis, 2014
  • Table 16: Product Profile - Warfarin
  • Table 17: Warfarin SWOT Analysis, 2014
  • Table 18: Product Profile - Lipitor
  • Table 19: Lipitor (atorvastatin) SWOT Analysis, 2014
  • Table 20: Product Profile - Crestor (rosuvastatin)
  • Table 21: Crestor (rosuvastatin) SWOT Analysis, 2014
  • Table 22: Product Profile - Zocor (simvastatin)
  • Table 23: Zocor (simvastatin) SWOT Analysis, 2014
  • Table 24: Commonly Used Beta Blockers
  • Table 25: Product Profile - Beta Blockers
  • Table 26: Beta Blockers SWOT Analysis, 2014
  • Table 27: Product Profile - Tekturna (aliskiren)
  • Table 28: Tekturna (aliskiren) SWOT Analysis, 2014
  • Table 29: Commonly Used ACE Inhibitors
  • Table 30: Product Profile - ACE Inhibitors
  • Table 31: ACE Inhibitor SWOT Analysis, 2014
  • Table 32: Commonly Used ARBs
  • Table 33: Product Profile - Angiotensin Receptor Blockers (ARBs)
  • Table 34: ARB SWOT Analysis, 2014
  • Table 35: Product Profile - Mineralocorticoid Receptor Antagonists (MRAs)
  • Table 36: MRA SWOT Analysis, 2014
  • Table 37: Unmet Need and Opportunity in Acute Coronary Syndrome
  • Table 38: Acute Coronary Syndrome - Clinical Trials by Phase and Status, 2014
  • Table 39: Acute Coronary Syndrome - Late-Stage Pipeline, 2014
  • Table 40: Comparison of Therapeutic Classes in Development for ACS, 2014
  • Table 41: Product Profile - Xarelto (rivaroxaban)
  • Table 42: Xarelto (rivaroxaban) SWOT Analysis, 2014
  • Table 43: Product Profile - Cangrelor
  • Table 44: Cangrelor SWOT Analysis, 2014
  • Table 45: Product Profile - Zontivity (vorapaxar)
  • Table 46: Vorapaxar SWOT Analysis, 2014
  • Table 47: Product Profile - Alirocumab (RGN727)
  • Table 48: Alirocumab SWOT Analysis, 2014
  • Table 49: Product Profile - Evolocumab (AMG 145)
  • Table 50: Phase III Clinical Trials of Evolocumab Reported by Amgen from Q4 2013 - Q1 2014
  • Table 51: Evolocumab SWOT Analysis, 2013
  • Table 52: Product Profile - Bococizumab (PF-04950615)
  • Table 53: Bococizumab (PF-04950615) SWOT Analysis, 2014
  • Table 54: Product Profile - Anacetrapib
  • Table 55: Anacetrapib SWOT Analysis, 2014
  • Table 56: Product Profile - Evacetrapib
  • Table 57: Evacetrapib SWOT Analysis, 2013
  • Table 58: Product Profile - Darapladib
  • Table 59: Darapladib SWOT Analysis, 2014
  • Table 60: Sales Forecasts ($m) for ACS in Japan, 2013-2023
  • Table 61: Key Events Impacting Sales for Acute Coronary Syndrome in Japan, 2014
  • Table 62: Acute Coronary Syndrome Market - Drivers and Barriers, 2014
  • Table 63: Acute Coronary Syndrome Market - Drivers and Barriers in Japan, 2014
  • Table 64: Key Launch Dates
  • Table 65: Key Patent Expiries
  • Table 66: Price Sources and Calculations, in US
  • Table 67: Physicians Surveyed, By Country

List of Figures

  • Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast
  • Figure 2: Progression of Coronary Artery Disease, Atherosclerotic Plaque Rupture, Thrombosis, and Acute Coronary Syndrome
  • Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis
  • Figure 4: Electrocardiography in the Diagnosis of ACS
  • Figure 5: Acute Coronary Syndrome Therapeutics - Clinical Trials by Phase in the 7MM, 2014
  • Figure 6: Competitive Assessment of Late-Stage Pipeline Agents for ACS, 2013-2023
  • Figure 7: Sales for Acute Coronary Syndrome in Japan by Drug Class, 2013-2023
Back to Top